Therapeutic B-cell depletion with obinutuzumab modulates key immunopathological pathways in lupus nephritis: an exploratory whole blood transcriptomic analysis of the phase II NOBILITY trial

In one of the most detailed molecular portraits yet of how a next-generation antibody rewrites the immune system in lupus, researchers have shown that obinutuzumab, a glycoengineered anti-CD20 therapy, leaves an unmistakable transcriptomic fingerprint in the blood of patients with lupus nephritis. The exploratory analysis, drawn from the phase II NOBILITY trial, sequenced the RNA of whole blood samples from 88 participants and revealed that a single course of obinutuzumab rapidly and persistently silenced 289 genes, most of them tied directly to the B-cell machinery that drives this devastating kidney disease. The findings, published in Frontiers in Lupus, offer the first cross-sectional and longitudinal transcriptomic evidence of how this antibody reshapes the lupus immune landscape at the molecular level.

The story begins with a therapeutic paradox. B cells sit at the heart of lupus nephritis pathogenesis, producing autoantibodies, presenting antigens and secreting inflammatory cytokines that fuel renal destruction. Yet when rituximab, a type I anti-CD20 antibody, was tested in this population, it failed to outperform standard immunosuppression. Investigators suspected the problem lay in incomplete and highly variable B-cell depletion, both in the blood and in the target tissues. Obinutuzumab was engineered to overcome precisely this weakness. As a type II anti-CD20 monoclonal antibody with a glycoengineered Fc region, it was designed to kill B cells more potently, relying less on complement-dependent cytotoxicity and more on direct cell death and antibody-dependent cellular cytotoxicity and phagocytosis, mechanisms collectively known as ADCC and ADCP.

That engineering paid off clinically. Both the phase II NOBILITY trial and the subsequent phase III REGENCY trial demonstrated that adding obinutuzumab to standard therapy with mycophenolate mofetil and glucocorticoids produced significantly higher rates of complete renal response than standard therapy alone. But what those trials could not reveal was the molecular choreography underneath. To capture it, the research team, led by scientists at Genentech and F. Hoffmann-La Roche, performed bulk RNA sequencing on blood samples collected at baseline, week 4, week 24 and week 52 from 88 of the 125 participants enrolled in NOBILITY, comparing 45 obinutuzumab-treated patients with 43 placebo recipients, all of whom also received background immunosuppression.

The results were striking in their speed and persistence. Within just four weeks, obinutuzumab had downregulated 236 genes relative to placebo, with only six genes upregulated. The most profoundly suppressed genes by absolute fold change included MS4A1, the gene encoding CD20 itself, along with PAX5, OSBPL10, FCRL5, COL19A1 and CD19, all highly expressed in the B-cell compartment. By week 52, 279 genes remained downregulated and eight upregulated compared with placebo, and 204 genes were consistently suppressed at both week 4 and week 52, indicating a sustained transcriptomic effect that persisted for the full year of the trial. In the placebo arm, by contrast, only one gene was downregulated at week 4, suggesting that background therapy alone had minimal immediate impact on the blood transcriptome.

To confirm that these gene expression changes reflected actual cell depletion rather than altered transcription within surviving cells, the team applied a deep learning deconvolution framework called Scaden, trained on a single-cell RNA sequencing reference from peripheral blood mononuclear cells of systemic lupus erythematosus patients. The model predicted a significant reduction in the B-cell fraction at weeks 4 and 52 in the obinutuzumab group relative to baseline, a change entirely absent in the placebo arm. This cellular deconvolution aligned perfectly with the known pharmacodynamics of obinutuzumab, confirming that the bulk transcriptomic signal was driven by the physical disappearance of B cells from the peripheral blood.

Perhaps the most compelling discovery involved a subset of B cells with an especially sinister reputation. Atypical B cells, sometimes called age-associated B cells or ABCs, are transcriptionally distinct, autoantibody-producing cells that have been implicated in the pathogenesis of both systemic lupus erythematosus and lupus nephritis. When the team mapped their top differentially expressed genes onto publicly available single-cell RNA sequencing data from 162 lupus patients using the Scanpy toolkit, they found that FCRL5, one of the most downregulated genes after obinutuzumab treatment, was specifically enriched in atypical B cells compared with other B-cell subsets and other peripheral blood mononuclear cells. This suggests that obinutuzumab has the potential to deplete this pathogenic population, although the authors caution that the finding likely reflects the overall depth of B-cell depletion rather than selective targeting of ABCs, and that direct demonstration in the NOBILITY trial has not yet been performed.

Beyond B-cell suppression, gene set enrichment analysis revealed a completely different molecular story unfolding in parallel. While Gene Ontology Biological Process terms associated with B-cell receptor signalling, proliferation and activation were strongly downregulated, a distinct signature of upregulated innate immune activity emerged. Pathways involving phagocytosis, inflammatory response mediators, lytic vacuole organisation and leucocyte degranulation were all enhanced in obinutuzumab-treated patients compared with placebo. The researchers hypothesise that this innate activation signature reflects engagement of ADCC and ADCP mechanisms driven by the glycoengineered Fc region of the antibody, consistent with the previously published type II mechanism of action. They also note an alternative possibility: that deep B-cell depletion therapies may trigger a compensatory innate immune response, a phenomenon recently observed in patients achieving remission through chimeric antigen receptor T-cell therapy, where similar phagocytosis-related signatures appeared alongside near-total B-cell aplasia.

One of the most clinically significant findings concerned Fc gamma receptor polymorphisms. Because obinutuzumab depends partly on Fc gamma receptors to mediate ADCC and ADCP, genetic variations in these receptors have historically been considered potential predictors of treatment response. The well-characterised low-affinity variants FCGR3A V158F and FCGR2A H131R are known to affect phagocytosis and correlate with lupus risk. Yet in this exploratory analysis of 36 genotyped obinutuzumab-treated participants, neither variant showed any significant association with sustained B-cell depletion or with complete renal response at week 52. The p-values for both comparisons were 1.0 or 0.81, suggesting that obinutuzumab achieved its efficacy independent of these historically limiting polymorphisms. The authors emphasise that the genotyped subset was small and the study was not powered to formally establish independence, but the results are hypothesis-generating and consistent with the antibody’s reduced reliance on high-affinity Fc gamma receptor variants.

Crucially, the transcriptomic changes induced by obinutuzumab occurred uniformly across all treated participants, regardless of whether they achieved complete renal response at week 52. At baseline, no differentially expressed genes distinguished future responders from non-responders, and at week 52, comparing obinutuzumab-treated responders to obinutuzumab-treated non-responders similarly yielded no significant differences. The authors attribute this to several known limitations of peripheral blood analyses in lupus nephritis. Whole blood RNA abundance may not fully reflect functional protein levels or post-translational modifications driving disease. More importantly, clinical response in NOBILITY was defined by kidney-specific parameters such as proteinuria and renal function, and systemic whole blood transcriptomics may not adequately capture the molecular activation states and local tissue repair mechanisms occurring within the kidney that ultimately determine these outcomes. The binary classification of clinical outcomes also means that the non-responder group inherently includes patients achieving partial renal response, who may be experiencing biological improvements that fall short of the strict complete response cut-off, thereby blurring potential transcriptomic differences between the two groups.

Placed in context with other lupus therapies, obinutuzumab occupies a unique mechanistic niche. Rituximab, the type I anti-CD20 antibody, can reduce B-cell pathway activity but its efficacy in lupus nephritis is thought to be limited by variable and incomplete depletion. Belimumab, which modulates B-cell survival by targeting B-cell activating factor, produces systemic transcriptomic changes including downregulation of B-cell-related pathways but has limited immediate effects on pathogenic subsets like memory B cells and plasmablasts. Anifrolumab, an anti-interferon receptor antibody, induced a broad signature of 3,737 differentially expressed genes in separate phase III analyses, highlighting the difference between targeted cell depletion and widespread pathway modulation. CD19 chimeric antigen receptor T-cell therapy sets the current benchmark with near-total B-cell aplasia and a deep immune reset that also involves activation of innate immune pathways. Against this landscape, the focused 287-gene signature at week 52 in the NOBILITY analysis reflects a highly targeted depletion strategy rather than broad immune pathway modulation, though the authors caution that direct numerical comparisons between studies are inherently limited by differences in patient cohorts, trial designs and statistical methodologies, including the strict fold-change threshold of greater than 1.5 alongside a false discovery rate below 0.05 applied in the NOBILITY analyses.

The study also predicted a high proportion of classical monocytes across both treatment arms, which the authors attribute to an artifact of using a peripheral blood mononuclear cell-based single-cell reference that lacks neutrophils. Given that neutrophils constitute a substantial fraction of whole blood but were absent from the training set, the Scaden model likely attributed neutrophil-derived reads to classical monocytes due to their shared myeloid lineage and overlapping transcriptional profiles, a caution against over-interpretation of the innate immune signal. Future studies using more direct methods such as high-parameter flow cytometry will be needed to confirm these findings and further characterise the effect of obinutuzumab on specific B-cell subsets like atypical B cells. The authors also suggest that future efforts may benefit from investigating specific cell types using single-cell transcriptomics and from correlating transcriptomic changes with broader measures of lupus disease activity, such as the SLE Disease Activity Index or the SLE Responder Index 4, which are less influenced by local kidney pathology than complete renal response.

For now, the molecular evidence reinforces the biological rationale for obinutuzumab in lupus nephritis, characterised by deep B-cell depletion and distinct innate immune activation consistent with its type II mechanism. The findings provide mechanistic insight into the pharmacodynamic basis of the antibody’s activity, showing for the first time both cross-sectional and longitudinal transcriptomic effects in this disease. What they do not yet explain is why some patients respond clinically while others do not, a question that the authors acknowledge warrants further investigation in larger cohorts. As B-cell depletion therapies continue to evolve from broad immunosuppression toward precision molecular interventions, this transcriptomic analysis stands as a template for how whole blood RNA sequencing can illuminate the pharmacodynamic effects of targeted antibodies in complex autoimmune disease, even when the clinical outcomes they ultimately drive remain stubbornly resistant to prediction from the peripheral blood alone.

Subject of Research: Therapeutic B-cell depletion with obinutuzumab modulates key immunopathological pathways in lupus nephritis: an exploratory whole blood transcriptomic analysis of the phase II NOBILITY trial

Article Title: Therapeutic B-cell depletion with obinutuzumab modulates key immunopathological pathways in lupus nephritis: an exploratory whole blood transcriptomic analysis of the phase II NOBILITY trial

Article References: Therapeutic B-cell depletion with obinutuzumab modulates key immunopathological pathways in lupus nephritis: an exploratory whole blood transcriptomic analysis of the phase II NOBILITY trial. (n.d.). https://doi.org/10.3389/flupu.2026.1794646

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1794646

Keywords: Therapeutic, B-cell, depletion, obinutuzumab, modulates, immunopathological, pathways, lupus, nephritis, exploratory, whole, blood